Plain-English translation of NCT03258320 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether four different chemotherapy medications—Cabazitaxel, Docetaxel, Mitoxantrone, or Satraplatin—given before prostate surgery can improve outcomes for men with high-risk prostate cancer. You would receive the medication through an IV (or by mouth for one option) once a week for 4 weeks, then have surgery to remove your prostate about 2–3 weeks later. The goal is to see if treating the cancer with chemotherapy first makes surgery more effective.
Most prostate cancers that are caught early can be cured with surgery alone, but high-risk cancers are more likely to spread or come back. Doctors want to know if chemotherapy given before surgery can destroy hidden cancer cells and reduce the chance of the cancer returning.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive one of four chemotherapy medications as an outpatient, given once weekly for 4 weeks. After a 2–3 week break to let your body recover, you will have surgery to remove your prostate. You will be compared to men who go straight to surgery without chemotherapy first. The entire treatment phase takes about 2 months, and you will have follow-up visits afterward to monitor your recovery and long-term outcome.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
China